Last reviewed · How we verify
Propess® (dinoprostone)
Propess® (dinoprostone) is a Prostaglandin F2α analog Small molecule drug developed by University Hospital, Clermont-Ferrand. It is currently FDA-approved for Labor induction in pregnant women at or near term, Cervical ripening prior to labor induction.
Dinoprostone is a prostaglandin F2α analog that stimulates uterine contractions and cervical ripening to induce labor.
Propess (dinoprostone) is a small molecule that acts as a prostaglandin E2 receptor agonist. It is used for cervical ripening and labor induction, typically administered via a controlled-release vaginal insert.
At a glance
| Generic name | Propess® (dinoprostone) |
|---|---|
| Sponsor | University Hospital, Clermont-Ferrand |
| Drug class | Prostaglandin F2α analog |
| Target | Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Obstetrics |
| Phase | FDA-approved |
Mechanism of action
Dinoprostone binds to prostaglandin F (FP) receptors on uterine smooth muscle, increasing intracellular calcium and triggering myometrial contractions. It also promotes cervical softening and dilation by increasing collagenase activity and promoting cervical remodeling, facilitating labor induction or augmentation.
Approved indications
- Labor induction in pregnant women at or near term
- Cervical ripening prior to labor induction
Common side effects
- Uterine hyperstimulation
- Fever
- Nausea and vomiting
- Diarrhea
- Abdominal pain
- Vaginal pain or irritation
Key clinical trials
- Mechanical cervicAl ripeninG for Women With PrOlongedPregnancies (PHASE3)
- Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening (PHASE3)
- Is There an Interest in Repeating the Vaginal Administration of Dinoprostone (Propess®), to Promote Induction of Labor of Pregnant Women at Term? (PHASE3)
- DOuble-BAlloon Versus PROstaglandin E2 for Cervical Ripening in Low Risk Pregnancies (NA)
- Artificial Induction of Labour in Full-term Singleton Pregnancy : Comparative Randomized Trial of Two Strategies (NA)
- Efficacy and Safety of Oral Misoprostol 25 μg vs. Vaginal Dinoprostone in Induction of Labor at Term
- What After the First Propess (PHASE2)
- An RCT of a Synthetic Osmotic Cervical Dilator for Induction of Labour in Comparison to Dinoprostone Vaginal insErt (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propess® (dinoprostone) CI brief — competitive landscape report
- Propess® (dinoprostone) updates RSS · CI watch RSS
- University Hospital, Clermont-Ferrand portfolio CI
Frequently asked questions about Propess® (dinoprostone)
What is Propess® (dinoprostone)?
How does Propess® (dinoprostone) work?
What is Propess® (dinoprostone) used for?
Who makes Propess® (dinoprostone)?
What drug class is Propess® (dinoprostone) in?
What development phase is Propess® (dinoprostone) in?
What are the side effects of Propess® (dinoprostone)?
What does Propess® (dinoprostone) target?
Related
- Drug class: All Prostaglandin F2α analog drugs
- Target: All drugs targeting Prostaglandin F receptor (FP receptor)
- Manufacturer: University Hospital, Clermont-Ferrand — full pipeline
- Therapeutic area: All drugs in Obstetrics
- Indication: Drugs for Labor induction in pregnant women at or near term
- Indication: Drugs for Cervical ripening prior to labor induction
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing